Replies to post #599206 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

It will be.

[Roman516]

Wow, your right per your comment,
"Nonsense NWBO isn’t even “billion” dollar technology."
After reviewing the S-Curve, marketing and sales potential for GBM and other solid tumor cancers,
NWBO could be a “$300 to $500 billion” dollar technology in just a few years.
Thanks for making your point clear, IMPO.

[ATLnsider]

Legend431, you’re right that NWBO is not valued at a billion dollars today. But, it is only a matter of time, and more milestones being achieved before NWBio is worth multiple tens of $billions, or even trillions.

Granted, this will take years, and for NWBio to successfully achieve several major positive milestones. Most of the NWBO investors here today will probably sell their shares long before the valuation of NWBio reach tens of billions, and especially trillions.

I took a quick look at how much NWBio will be worth, assuming the following:

(1) DCVax-L is approved initially in the US, UK, Canada, Germany and the rest of the EU.

(2) DCVax-L is approved in most of the rest of the world.

(3) DCVax-L is eventually approved as a tissue agnostic treatment for all or most solid tumor cancers. I gradually increased annual global patients each year.

(4) The average revenue per patient for DCVax-L starts out initially at $150,000 per patient. Then because of manufacturing efficiencies due to using Flaskworks devices, and economies of scale due to an increasing number of customers treated each year, the revenue per patient would gradually decrease by about 50%, from $150,000 down to $75,000.

(5) The average multiple of price to sales for a biotech drug company is 5.78. I used this multiple to calculate the total valuation of NWBio for each level of customers treated:

https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html

(6) The value per share is initially based on 1.5 billion shares outstanding. I increased the number of outstanding shares to 1.6 billion shares after the annual number of cancer patients treated exceeded 10,000 patients per year.

Here are the results of these projections below. You can see an eventual valuation of over $1.73 trillion, which equates to $1,083.75 per share, based on 1.6 billion NWBO shares outstanding: